ALM 005
Alternative Names: ALM-005Latest Information Update: 25 Jul 2022
At a glance
- Originator Almatica Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 11 Jul 2022 Phase-I clinical trials in Unspecified in USA (unspecified route) (Almatica Pharma pipeline; July 2022)